Independence Edge

Coverage of Zepbound^TM (tirzepatide) under the obesity management policy

As previously announced in Edge, we have updated the criteria for coverage of weight management medications under the obesity management policy. The FDA recently approved a combination glucose‑dependent insulinotropic polypeptide (GIP) receptor and glucagon‑like peptide‑1 (GLP‑1) receptor agonist branded product, Zepbound. Coverage for Zepbound, including under the new program options offered for self‑funded groups, will follow the same criteria as Wegovy^® (semaglutide) and Saxenda^® (liraglutide). We have updated the article to reflect this addition.  Full Article

Consolidated Appropriations Act: Gag Clause attestation submission

Independence Blue Cross (IBX) and Independence Administrators (IA) have submitted the annual Gag Clause attestation on behalf of fully insured and self‑funded groups that did not opt out of having IBX and IA submit it on their behalf. There is nothing further required at this time by these clients. For more information, reference the latest CAA and TCR FAQs for IBX and IA.

Healthy You!

Check out the latest issue of Healthy You!, our monthly newsletter of reliable, engaging information that educates members on a variety of health and well‑being topics.